Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Clinical and Economic Outcome Analysis of First-Line Immunosuppression in Acquired Hemophilia a

Ellen Cusano, Julia Hews-Girard, Mujtaba Basharat, Lindsay Cowley, Julie Grabell, Nancy Hodgson, Kelly Pittman, Allison Rupnaraine, Rowan Thillaye-Kerr, Brendan Cord Lethebe, Paula James, Roy Khalife, Natasha Pardy, Chai W. Phua, Oksana C. Prokopchuk-Gauk, Michelle Sholzberg, Haowei Linda Sun, Man-Chiu Poon, M. Dawn Goodyear

Blood (2024) 144 (Supplement 1): 554.

https://doi.org/10.1182/blood-2024-202551

Published: 2024

Journal Articles

Appropriateness of Immunosuppression and Blood Product Utilization in Acquired Hemophilia A: A Multicentre Provincial Practice Audit

Bradley Rutherford, Ellen Cusano, M. Dawn Goodyear, Haowei (Linda) Sun

Blood (2023) 142 (Supplement 1): 2313.

https://doi.org/10.1182/blood-2023-187702

Published: 2023

Journal Articles

Prevalence and Risk Factors of Diagnostic Delays in Acquired Hemophilia A

Bradley Rutherford, Ellen Cusano, M. Dawn Goodyear, Haowei (Linda) Sun

Blood (2023) 142 (Supplement 1): 2627.

https://doi.org/10.1182/blood-2023-185210

Published: 2023

Journal Articles

Comparison of Activated Clotting Time to Hepcon Protamine Titration for Anticoagulation Management during Cardiopulmonary Bypass Surgery in a Patient with Severe Hemophilia a on Emicizumab Prophylaxis

Ellen Cusano, Haowei Linda Sun, M Dawn Goodyear, Man-Chiu Poon, Douglas Seal, R Scott McClure, Natalia Rydz

Blood (2022) 140 (Supplement 1): 2759–2761.

https://doi.org/10.1182/blood-2022-168133

Published: 2022

Journal Articles

Case Series: Outcome and Cost Analysis of Rituximab Versus Non-Targeted Immunosuppression As First Line Inhibitor Eradication in Acquired Hemophilia a

Ellen Cusano, Adrienne Lee, MD, Julia Hews-Girard, RN BScN MN

Blood (2019) 134 (Supplement_1): 2399.

https://doi.org/10.1182/blood-2019-129665

Published: 2019

NARROW

Clinical and Economic Outcome Analysis of First-Line Immunosuppression in Acquired Hemophilia a

Appropriateness of Immunosuppression and Blood Product Utilization in Acquired Hemophilia A: A Multicentre Provincial Practice Audit

Prevalence and Risk Factors of Diagnostic Delays in Acquired Hemophilia A

Comparison of Activated Clotting Time to Hepcon Protamine Titration for Anticoagulation Management during Cardiopulmonary Bypass Surgery in a Patient with Severe Hemophilia a on Emicizumab Prophylaxis

Case Series: Outcome and Cost Analysis of Rituximab Versus Non-Targeted Immunosuppression As First Line Inhibitor Eradication in Acquired Hemophilia a

Email alerts

ASH Publications

American Society of Hematology

Clinical and Economic Outcome Analysis of First-Line Immunosuppression in Acquired Hemophilia a

Appropriateness of Immunosuppression and Blood Product Utilization in Acquired Hemophilia A: A Multicentre Provincial Practice Audit

Prevalence and Risk Factors of Diagnostic Delays in Acquired Hemophilia A

Comparison of Activated Clotting Time to Hepcon Protamine Titration for Anticoagulation Management during Cardiopulmonary Bypass Surgery in a Patient with Severe Hemophilia a on Emicizumab Prophylaxis

Case Series: Outcome and Cost Analysis of Rituximab Versus Non-Targeted Immunosuppression As First Line Inhibitor Eradication in Acquired Hemophilia a

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only